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Abstract (250/(250 words max)) 
Background: Neurofilament light chain (NFL), an axonal cytoskeletal protein reported to 
maintain neuronal integrity, is elevated in the cerebrospinal fluid and blood in Alzheimer’s 
disease (AD).  
Objective: Investigate the association of plasma NFL with preclinical-AD features, such as 
high neocortical amyloid-β load (NAL) and subjective memory complaints, and cognitive 
performance in cognitively normal older adults.  
Methods: Plasma NFL concentrations were measured employing the single molecule array 
(Simoa) platform in participants from the KARVIAH cohort, aged 65-90 years. Participants 
underwent a battery of neuropsychological testing to evaluate cognitive performance and were 
categorised as low NAL (NAL-, n=65) and high NAL (NAL+, n=35) assessed via positron 
emission tomography, and further stratified into subjective memory complainers (SMC; 
nNAL-=51, nNAL+=25) and non-SMC (nNAL-=14, nNAL+=10) based on the Memory 
Assessment Clinic–Questionnaire (MAC-Q).  
Results: Plasma NFL inversely correlated with global cognition, verbal and visual episodic 
memory and, executive function and working memory. No significant difference in NFL was 
observed between NAL+ and NAL- participants, however within APOEε4 non-carriers, higher 
NAL was observed in individuals with NFL concentrations within quartiles3 and 4(vs 
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quartile1). Additionally, within the NAL+ participants, SMC had a trend of higher NFL 
compared to non-SMC.  
Conclusion: Plasma NFL is inversely associated with cognitive performance in elderly 
individuals. While plasma NFL may not reflect NAL in individuals with normal global 
cognition, the current observations indicate that it may be used to track onset of axonal injury 
in NAL+ individuals. It could thus potentially serve as a biomarker to tell when amyloid 
pathology has entered the neurotoxic phase.  
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Introduction 
Neurofilament (NF) is a crucial axonal cytoskeletal component comprising three subunits, 
namely, neurofilament light chain (NFL), neurofilament medium chain (NFM) and 
neurofilament heavy chain (NFH) [1]. The disruption of NF in neuronal damage occurring 
within neurodegenerative conditions, results in the release of NF into the cerebrospinal fluid 
(CSF) [2]; consequently giving rise to elevated NFL concentrations in the CSF, as has been 
reported in Alzheimer’s disease (AD) [3] and other neurodegenerative diseases [4-7].  
With the invasive nature of CSF collection via lumbar puncture, the potential of employing 
NFL as a biomarker for disease diagnosis or progression, and possibly for screening, further 
drove the investigation of blood NFL alterations, in disease [2, 8-10]. Employing the 
Alzheimer’s Disease Neurodegenerative Initiative (ADNI) cohort, Mattsson and colleagues 
reported significantly higher plasma NFL in AD and mild cognitively impaired (MCI) patients 
compared to controls [11]. Additionally, higher plasma NFL has been associated with 
compromised cognition and hippocampal atrophy both cross-sectionally and longitudinally. 
Furthermore, plasma NFL was inversely associated with brain glucose metabolism, 
longitudinally in the same highly characterized ADNI cohort [11]. More recently, a study 
conducted on autosomal dominant Alzheimer’s disease (ADAD) families found that plasma 
NFL was higher in the asymptomatic mutation carriers (aMC) and symptomatic mutation 
carriers (sMC) compared to their non-carrier (NC) relatives, wherein plasma NFL 
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concentrations were reported to be about 1.3-fold higher in aMC and 3.6-fold higher in sMC 
[12].  
However, plasma NFL in individuals with preclinical AD prior to cognitive impairment, 
characterised by neocortical amyloid-β load (NAL) measured via positron emission 
tomography (PET) and subjective memory complaints, has not been investigated previously. 
Furthermore, the association between plasma NFL and cognitive performance in cognitively 
normal elderly individuals has also not been examined. 
Therefore, the current study investigated the association between plasma NFL and NAL, 
employing a standard uptake value ratio (SUVR) cut-off value of 1.35, categorising study 
participants as high NAL (SUVR≥1.35; NAL+) and low NAL (SUVR<1.35; NAL-), given that 
the aberrant build-up of NAL begins as early as two decades prior to the clinical manifestation 
of AD [13]. Based on the Memory Assessment Clinic–Questionnaire (MAC-Q) [14], NAL+ 
participants were further categorised into subjective memory complainers (SMC) and non-
complainers (non-SMC) to examine NFL alterations within the preclinical cohort subset at 
highest risk of AD (NAL+ SMC). The current study also examined whether plasma NFL levels 
inversely correlated with cognitive performance within cognitively normal elderly individuals. 
Our investigations were therefore aimed at gaining better insight into whether axonal injury, 
reflected by increased plasma NFL, is present in the early pathogenesis of AD. 
Methods 
Participants 
Study participants belonged to the Kerr Anglican Retirement Village Initiative in Ageing 
Health (KARVIAH) cohort, at baseline. All participants were residents of Anglicare, New 
South Wales, Australia.  
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Cohort volunteers (N=206) were required to meet the set screening inclusion and exclusion 
criteria to be eligible for the KARVIAH cohort. Briefly, the inclusion criteria for the 
KARVIAH cohort comprised an age range of 65-90 years, good general health, no known 
significant cerebral vascular disease, fluent in English, adequate/corrected vision and hearing 
to enable testing, no objective cognitive impairment as screened by a Montreal Cognitive 
Assessment (MoCA) score ≥26. MoCA scores lying between 18-25 were assessed on a case 
by case basis by the study neuropsychologist following stratification of scores according to age 
and education [15]. The exclusion criteria comprised, the diagnosis of dementia based on the 
revised criteria from the National Institute on Aging - Alzheimer's Association [16], presence 
of acute functional psychiatric disorder (including lifetime history of schizophrenia or bipolar 
disorder), history of stroke, severe or extremely severe depression (based on the depression, 
anxiety, stress scales; DASS) and uncontrolled hypertension (systolic BP > 170 or diastolic BP 
> 100).  
One hundred and five participants out of the 134 volunteers meeting the inclusion/exclusion 
criteria, underwent neuroimaging, neuropsychometric evaluation and blood collection, as the 
remaining either declined undergoing neuroimaging or withdrew from the study. Within these 
105 participants, 100 participants were considered to have normal global cognition based on 
their Mini-Mental State Examination score [17] (MMSE ≥26), and were included in the current 
study. Plasma NFL concentrations were reported in all 100 participants considered to have 
normal global cognition. All volunteers provided written informed consent prior to 
participation, and the Bellberry Human Research Ethics Committee, Australia, provided 
approval for the study.   
Evaluation of neocortical amyloid-β load via PET  
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All study participants were imaged within three months of blood collection. Participants 
underwent positron emission tomography (PET) using ligand 18F-Florbetaben (FBB) at 
Macquarie Medical Imaging in Sydney. Participants were administered an intravenous bolus 
of FBB slowly over 30s, while in a rested position. Images were acquired over a 20 min scan, 
in 5 min acquisitions, beginning 50 min post injection. Neocortical amyloid-β load was 
calculated as the mean SUVR of the frontal, superior parietal, lateral temporal, lateral occipital, 
and anterior and posterior cingulate regions using image processing software, CapAIBL [18, 
19].  
Blood collection, APOE genotyping, measurement of plasma NFL 
All study participants fasted for a minimum of 10 hours overnight prior to blood withdraw 
employing standard serological methods and processing [20]. Apolipoprotein E (APOE) 
genotype was determined from purified genomic DNA extracted from 0.5 ml whole blood as 
previously described [20]. 
Plasma NFL concentrations were measured employing the ultra-sensitive single-molecule 
array (Simoa) platform [10, 11]. Calibrators were run in duplicates and samples were run in 
singlicates with a 4-fold dilution. Two quality control (QC) levels were run in duplicates at the 
beginning and the end of each plate. For QC with concentration 12.1 pg/mL, repeatability and 
intermediate precision were 20.2 % while for QC with concentration 155.8 pg/mL, repeatability 
was 14.6 % and intermediate precision was 14.9 %. The lowest limit of quantification was 6 
pg/mL. 
Neuropsychological tests 
All study participants underwent a comprehensive battery of neuropsychological testing. The 
full battery comprised the MoCA [15], MMSE [17], MAC-Q [14], Rey Auditory Verbal 
Learning Test (RAVLT) [21], Logical Memory (LM) I and II (WMS‐III; Story A only) [22], 
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Rey Complex Figure Test (RCFT)[23], Wechsler Adult Intelligence Scale – Third edition 
(WAIS–III) Digit Span [24], WAIS–III Digit Symbol Substitution Test (DSST) [25], D-KEFS 
Category Fluency (Boys Names) and Switching (Fruits and Furniture) Tasks [26], Controlled 
Oral Word Association Test [27], Stroop Test (Victoria version) [28], the Boston Naming Test 
[29], Wechsler Test of Adult Reading [30] and the DASS [31]. Composite scores were 
generated for verbal and visual episodic memory and for working memory and executive 
function. The verbal and visual episodic memory composite score was created from the mean 
of the Z‐scores of RAVLT List A, RAVLT short delay, RAVLT long delay, LM I, LMII, RCFT 
3 min and RCFT 30 min while the working memory and executive function composite score 
was generated from the mean of the Z‐scores of Digit Span backward, DSST, D-KEFS Boys 
names and Fruits and Furniture Switching tasks. The global composite score was constructed 
from the mean of the Z‐score measures of RAVLT List A, RAVLT short delay, RAVLT long 
delay, LM I, LM II, RCFT 3 min, RCFT 30 min, Digit Span backward, DSST, D-KEFS Boys 
names and Fruits and Furniture Switching tasks and MMSE.  
 
Statistical analyses  
Descriptive statistics including means and standard deviations were calculated for NAL+ and 
NAL- groups. Chi-square tests were employed to compare the frequency of gender, APOE ε4 
carrier status and SMC between NAL+ and NAL- groups. Additionally, linear models were 
employed to compare continuous variables examined in the study between groups of interest 
(e.g. NAL- vs. NAL+, NAL+/non-SMC vs. NAL+/ SMC, NFL quartiles Q1 vs. Q2, Q3, Q4 
etc.) with and without adjusting for covariates age, gender and APOE ε4 carrier status. 
Continuous response variables were tested for approximate normality and variance 
homogeneity, and log transformed when required to satisfy test criteria. Pearson’s correlation 
coefficient was employed to investigate correlations between NFL and other continuous 
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variables of interest, except for the correlation between NFL and MMSE where Spearman’s 
correlation was used. Partial correlations were used when associations investigated were 
adjusted for age. All analyses were carried out using IBM® SPSS® Version 23. 
 
Results 
Demographic characteristics of study participants have been represented in Table 1, wherein 
no significant differences were observed between NAL- and NAL+ participants, except for the 
expected observation of a significantly higher APOE ε4 carrier frequency in the NAL+ group. 
Plasma NFL was observed to correlate with age (r=.533, p<.0001) while no significant 
association between plasma NFL was observed with education (r= -.004, p=.965), gender 
(mean±SD: males, 39.26±20.55 pg/mL; females, 35.02±16.30 pg/mL; p=.268) or APOE ε4 
carriage (mean±SD: non-carriers, 37.49±18.29 pg/mL; carriers, 32.18±15.39 pg/mL; p=.226).  
Plasma NFL was not observed to be significantly elevated in NAL+ participants (or preclinical 
AD) compared to NAL- participants (mean±SD: NAL-, 35.23±17.27 pg/mL; NAL+, 
38.50±18.75 pg/mL) with (p=.563) and without (p=.384) adjusting for age, gender and APOE 
ε4, however, a trend of elevated plasma NFL concentrations was observed in NAL+ SMC 
compared to NAL+ non-SMC, adjusting for age, gender and APOE ε4 carrier status (mean±SD, 
NAL+/non-SMC (n=10): 31.50±12.57 pg/mL, NAL+/SMC (n=25): 41.30±20.26 pg/mL; 
p=.069).  
Additionally, after stratifying the cohort into APOE ε4 carriers (n=21) and non-carriers (n=79), 
within the APOE ε4 non-carrier subset, participants carrying NFL concentrations lying within 
quartile 1 were observed to have significantly lower NAL (1.15±0.13) compared to those in 
quartiles 3 (1.32±0.29, p=.031) and 4 (1.38±0.32, p=.006, Figure 1). However, after adjusting 
for age, significance disappeared between quartile 1 and 3, and only a trend remained between 
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quartile 1 and 4 (p=.068), likely due to the strong correlation between NFL and age, 
confounding associations of NFL with other age-related outcomes within the scope of this 
modest sample size. 
Plasma NFL correlated inversely with verbal and visual episodic memory (r= -.305, p=.002) 
and working memory and executive function (r= -.357, p=.0002) in all participants (Figure 2). 
Plasma NFL was also observed to correlate inversely with global cognition assessed via MMSE 
(r= -.326, p=.001) and the global composite score (r= -.407, p<.0001) (Figure 2). On adjusting 
for age, plasma NFL continued to significantly correlate inversely with working memory and 
executive function (r= -.200, p=.047) and the global composite score (r= -.223, p=.026). 
 
Discussion 
Plasma NFL concentrations were not significantly elevated in cognitively normal elderly 
NAL+ versus NAL- participants. Our findings are in line with those reported by Mattsson and 
colleagues wherein no significant difference in plasma NFL was observed between NAL- 
(based on CSF Aβ42 ≥192 ng/L, n=71) and NAL+ (based on CSF Aβ42 <192 ng/L, n=41) 
cognitively normal participants [11]. Furthermore, associations between brain atrophy and 
plasma (and CSF) NFL concentrations reported previously in MCI, AD (and cognitively 
normal) individuals with both high and low CSF Aβ load [32], indicate that NFL is a general 
neurodegeneration biomarker, with high levels in many disorders such as PSP and FTD (Ref – 
se intro), which also is consistent with the observations of NFL between NAL+ and NAL- 
participants in the current study. However, we observed a trend of elevated plasma NFL in 
SMC compared to non-memory complainers within the NAL+ subset employed in the current 
study - the cohort subset likely to be the most advanced in the preclinical AD pathogenesis 
trajectory.  
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Interestingly, Mattsson and colleagues, also observed that MCI and AD APOE ε4 non-carriers 
had significantly higher plasma NFL concentrations compared to ε4 carriers. Within the current 
study as well, APOE ε4 non-carriers had a higher mean plasma NFL (37.49 pg/ml) compared 
to APOE ε4 carriers (32.18 pg/ml), although it did not reach significance presumably due to 
the relatively small numbers in the latter group. However, within the APOE ε4 non-carrier 
cohort subset, a trend of higher NAL was observed in participants with plasma NFL lying 
within Q3 and Q4 compared to Q1, suggesting that the onset of axonal cytoskeletal disruption 
may commence as early as this preclinical phase of AD.  
Within the current study we did not observe a significant correlation between plasma NFL and 
hippocampal atrophy (data not shown): an observation in line with findings reported by Pereira 
and colleagues, wherein plasma NFL was associated with brain atrophy only in symptomatic 
cases, while CSF NFL concentrations were associated with brain atrophy in AD, MCI and 
cognitively normal subjects [32]. Similar observations have also been reported in the autosomal 
dominant form of AD (ADAD) by Weston and colleagues [12]. No association between plasma 
NFL and neocortical glucose metabolism (data not shown) was observed within the current 
cross-sectional study, which is in agreement with the findings reported by Mattsson and 
colleagues [11].     
Plasma NFL was observed to correlate strongly with age in the present study. This correlation 
is consistent with previous studies reporting significant correlations between age and NFL in 
both, CSF and plasma (or serum) from healthy controls, individuals with pre-symptomatic 
neurodegenerative disease and within cohorts comprising healthy controls, MCI and AD 
patients [3, 7, 9, 11, 33, 34].  
Additionally, plasma and CSF NFL concentrations have previously been reported to be 
inversely associated with MMSE, the AD assessment scale–cognitive subscale, Clinical 
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Dementia Rating Scale and the Trail Making Test-B scores in participants with MCI, sporadic 
AD, ADAD and bipolar disorder [3, 11, 12, 35]. The current study also observed that plasma 
NFL correlated inversely with cognitive performance, particularly, verbal and visual episodic 
memory, executive function and working memory and global cognition suggesting that higher 
plasma NFL concentrations are associated with inferior cognitive performance in elderly 
individuals with normal global cognition as well. 
We acknowledge that the current study has limitations with regard to its relatively modest 
sample size. However, the present study also has its strengths given that it utilizes a highly 
characterised, cognitively normal cohort with a  representative proportion of preclinical AD 
individuals, in agreement with other established cohorts [36, 37], employing PET for NAL 
measurement, a stronger marker of AD neuropathology compared to CSF Aβ, as employed 
previously [11]. Additionally, the study also incorporates a comprehensive battery of 
neuropsychological tests and most importantly, a highly sensitive assay to measure plasma 
NFL. Further investigation of the association between NAL and NFL in cognitively normal 
elderly individuals via an orthogonal method, for example mass-spectrometry (MS), may be 
employed for validation given the differences between immune-assay based techniques and 
MS: Immune-based methods detect both modified and unmodified members of a specific 
protein species, as well as possible oligomeric forms.   but also potentially bind to other off-
target proteins in the sample, as the monoclonal antibody recognises an epitope which may also 
be presented in an unrelated protein. In contrast, the exact primary sequence of the peptide 
being measured is known in MS, however this technology only measures those peptides that 
are unmodified therefore restricting itself to a subset of all the isoforms of a specific protein 
carrying that sequence. Additionally, differences between native folded protein and denatured 
protein also contribute to disparities in measurements of the same protein employing 
orthogonal techniques.  
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To summarise, plasma NFL was not significantly higher in NAL+ versus NAL- cognitively 
normal elderly individuals, however a trend of elevated plasma NFL was observed within the 
NAL+ SMC (the cohort subset likely to be the farthest in the preclinical AD pathogenesis 
trajectory), indicating onset of axonal injury occurs well before the onset of clinical AD 
symptoms. Additionally, significant associations were observed between plasma NFL and 
neuropsychometric parameters representing visual and verbal memory, executive function and 
working memory and global cognition, in the current study. Our current plasma NFL 
observations along with those previously published indicate that plasma NFL alterations begin 
to manifest within the end stage of preclinical AD, and while NFL is not a sufficient stand-
alone marker for preclinical and clinical AD, it has the potential to serve as an early marker of 
neurodegeneration. Moreover, given that plasma NFL correlated with cognition, it is a 
promising biomarker for disease progression and for monitoring disease modifying therapies, 
reaffirming the potential of elevated plasma NFL as a marker of progressive 
neurodegeneration.  
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